Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated (
NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT SECURITIES INVESTIGATION: Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law ViolationsNEW YORK, NY - February 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
3 Small-Cap Stocks We Think Twice AboutSmall-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
3 Cash-Producing Stocks We’re Skeptical OfWhile strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law ViolationsNEW YORK, NY - February 14, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
Inspire Medical Systems, Astrana Health, Evolent Health, Corcept, and Centene Stocks Trade Up, What You Need To KnowA number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. While the market's reaction was initially described as a "bumpy ride" due to concerns in other sectors, the favorable inflation data ultimately helped calm Wall Street. Lower inflation is a key prerequisite for the central bank to ease its monetary policy, which is generally supportive of stock valuations.
CORT INVESTIGATION REMINDER: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORT INVESTIGATION REMINDER: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - February 13, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law ViolationsNEW YORK, NY - February 12, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
CORCEPT THERAPEUTICS INVESTIGATION ALERT: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - February 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law FirmLOS ANGELES, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (
NASDAQ: CORT) for violations of the securities laws.
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT)NEW YORK, NY - February 7, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - February 6, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law ViolationsNEW YORK, NY - February 5, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
